Active substance
Naftifine
- SFDA 1
- US FDA 10
- US price lines 5
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EXODERIL CREAM 1% | 1 % | Cream · Topical | 1 Tube | SAR 15.85 | NCE · Prescription | Sandoz GmbH | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NAFTIN | 2% | cream · topical | LEGACY | Prescription | 29 Feb 1988 |
| NAFTIN | 2% | gel · topical | LEGACY | Prescription | 27 Jun 2013 |
| NAFTIFINE HYDROCHLORIDE | 2% | cream · topical | SUN PHARMA CANADA | Prescription | 6 Jan 2016 |
| NAFTIFINE HYDROCHLORIDE | 1% | cream · topical | SUN PHARMA CANADA | Prescription | 8 Sep 2016 |
| NAFTIFINE HYDROCHLORIDE | 2% | gel · topical | SUN PHARMA CANADA | Prescription | 10 Apr 2019 |
| NAFTIFINE HYDROCHLORIDE | 2% | cream · topical | XIROMED | Prescription | 22 Sep 2020 |
| NAFTIN | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · topical | LEGACY | Discontinued | 29 Feb 1988 |
| NAFTIN | 1% | gel · topical | LEGACY | Discontinued | 18 Jun 1990 |
| NAFTIFINE HYDROCHLORIDE | 2% | cream · topical | AMNEAL | Discontinued | 10 Apr 2017 |
| NAFTIFINE HYDROCHLORIDE | 1% | gel · topical | AMNEAL | Discontinued | 20 Mar 2019 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NAFTIFINE HCL 1% CREAM | $4.19287 | per GM | 23 Sep 2026 |
| US NADAC | NAFTIFINE HCL 2% CREAM | $2.18907 | per GM | 23 Sep 2026 |
| US NADAC | NAFTIFINE HCL 2% CREAM | $1.80609 | per GM | 23 Sep 2026 |
| US NADAC | NAFTIFINE HCL 2% GEL | $8.5652 | per GM | 18 Mar 2026 |
| US NADAC | NAFTIFINE HCL 2% GEL | $8.9536 | per GM | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 30 Apr 2018 NAFTIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 10 Nov 2016 NAFTIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.